ClinicalTrials.gg
Active, not recruitingNCT04797000Updated Oct 20, 2026

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

A Phase 2 interventional study of Eltrombopag and Placebo in Myelodysplastic Syndromes, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 20 sites in Japan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing eltrombopag in Myelodysplastic Syndromes — none open to participants now, 2 under way, none of them phase 3. eltrombopag · Myelodysplastic Syndromes.

Enrollment
6th of 13
36 · median 30
Started
2021
the only one that year
Phase 2
8 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
4 of 13
Novartis Pharmaceuticals

Among the 13 studies testing eltrombopag in Myelodysplastic Syndromes, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 8 in phase 2, and was the 12th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 13 studies testing eltrombopag in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 20 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing eltrombopag in Myelodysplastic Syndromes as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).

Read the detailed description

This is a randomized, double-blind, placebo-controlled, Japanese local phase II study to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk MDS (IPSS-R very low, low, intermediate risk with bone marrow blast count \< 5% and cytogenetic very good, good or intermediate risk). Platelet transfusion dependence at baseline is defined as receiving platelet transfusion regularly with a frequency of 2 or more times within 4 weeks prior to randomization. Platelet transfusion should be performed for a patient with platelet counts \< 20 X 10\^9/L, or with hemorrhagic symptoms and platelet counts \< 30 X 10\^9/L.

The primary objective is to demonstrate superiority of eltrombopag versus placebo in terms of the proportion of participants who achieve platelet transfusion independence at Week 24.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Phase II
  • eltrombopag
  • ETB115
  • lower-risk MDS patients with platelet transfusion dependence
  • TPO-RA
  • placebo
  • myelodysplastic syndromes (MDS)
  • platelet transfusion dependence
04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with MDS according to the WHO classification revised 4th edition by investigator assessment with one of the following prognostic risk categories, based on the International

Prognostic Scoring System (IPSS-R):

  • very low (0-1.5)
  • low (2-3)
  • intermediate risks (3.5-4.5) All following criteria for prognostic variables per IPSS-R should be met.
  • Bone marrow blast \< 5% (per both investigator's assessment and central review)
  • Cytogenetic very good, good or intermediate risk corresponding to IPSS-R

    • transfusion dependence
    • , intolerant to, or ineligible for MDS treatments
    • (ECOG) Performance status (PS) 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of prior administration of eltrombopag, romiplostim, or other TPO-RA
  • Therapy-related MDS per WHO classification revised 4th edition
  • MDS/myeloproliferative neoplasms including chronic myelomonocytic leukaemia per the WHO classification revised 4th edition
  • MDS with excess blasts (EB) per WHO classification revised 4th edition
  • Known history of IPSS-R high or very high risk MDS
  • Currently receiving treatments for MDS (e.g., HMA, cyclosporine A (CsA) or lenalidomide). Supportive treatment with erythropoiesis-stimulating agents (ESAs) or erythroid mutation agent in anemic patients or granulocyte-colony stimulating factor (G-CSF) in patients with severe neutropenia and recurrent infections is allowed if at stable dosage for 3 months prior to screening and continued at the same dosing/schedule until the optimal dose of eltrombopag has been established.
  • Patients scheduled for hematopoietic stem cell transplantation
  • Bone marrow fibrosis that leads to an inability to aspirate adequate bone marrow sample
  • Known thrombophilic risk factors (except in cases where potential benefits of participating in the study outweighed potential risks of thromboembolic events (TEE), as determined by the investigator)

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Eltrombopag Arm

    Participants randomized to a 1: 1 ratio will take eltrombopag.

    Drug: Eltrombopag

  • Placebo comparator
    Placebo Arm

    Participants randomized to a 1: 1 ratio will take Placebo.

    Drug: Placebo

Interventions

  • Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)

    Also known as: ETB115

  • DrugPlacebo

    Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)

06

What researchers measure

Primary outcomes

  1. Percentage of participants who achieve platelet transfusion independence at Week 24

    Platelet transfusion independence is defined as the absence of platelet transfusion for at least 8 weeks. Platelet count should be higher than the baseline count.

    Time frame: Week 24

Secondary outcomes

  1. Time to platelet transfusion independence

    This is defined as time from the date of randomization to the first day of a platelet transfusion-free period lasting at least 8 weeks.

    Time frame: Year 1, Year 2

  2. Duration of platelet transfusion independence

    This is defined for participants who have achieved platelet transfusion independence only and will be calculated from the first date of platelet transfusion-free resulting in achievement of transfusion independence to the date before becoming platelet transfusion dependent.

    Time frame: Year 1, Year 2

  3. Percentage of participants with platelet transfusion independence

    Platelet transfusion independence is defined as the absence of platelet transfusion for at least 8 weeks. Platelet count should be higher than the baseline count.

    Time frame: Year 1, Year 2

  4. Percentage of participants with platelet transfusion frequency reduction at Week 24

    This is defined as a reduction by at least 50 percent during the 4 prior weeks as compared to the 4 weeks prior to randomization.

    Time frame: Week 24

  5. Percentage of participants with platelet response (Hematologic improvement (HI) - platelet))

    Platelet response is defined as HI-platelet per International Working Group criteria.

    Time frame: Week 24, Year 1, Year 2

  6. Time to platelet response

    This is defined as time from the date of randomization to the first date of achieving the platelet response criteria per modified IWG criteria.

    Time frame: Week 24, Year 1, Year 2

  7. Duration of platelet response

    This is defined for participants who have achieved platelet response and will be calculated from the first date of achieving the platelet response criteria to the date before loss of platelet response per modified IWG criteria.

    Time frame: Week 24, Year 1, Year 2

  8. Percentage of hematologic improvement-erythroid and -neutrophil

    per modified IWG criteria at 24 weeks, Year 1 and 2

    Time frame: Week 24, Year 1, Year 2

  9. Percentage of participants with disease progression excluding relapse after HI

    This is with regards to blast counts for both investigator assessment and central review per modified IWG criteria.

    Time frame: Week 24, Year 1, Year 2

  10. Percentage of participants with relapse after HI and transfusion independence

    The percentage of participants with relapse after HI and transfusion independence at Week 24, Year 1 and 2.

    Time frame: Week 24, Year 1, Year 2

  11. Percentage of participants with progression to Acute myeloid leukemia (AML)

    This is defined as ≥ 20% blasts at Week 24, Year 1 and 2 for both investigator assessment and central review per WHO classification revised 4th edition.

    Time frame: Week 24, Year 1, Year 2

  12. Leukemia free survival (LFS)

    This is defined as time from the date of randomization to progression to AML per WHO classification revised 4th edition of ≥ 20 percent blasts or death due to any cause for both investigator assessment and central review.

    Time frame: Week 24, Year 1, Year 2

  13. Clinically significant bleeding events

    This is defined as ≥ grade 2 events as per WHO bleeding scale.

    Time frame: Week 24, Year 1, Year 2

  14. Overall survival (OS)

    OS is defined as time from randomization to death due to any cause.

    Time frame: Week 24, Year 1, Year 2

  15. Quality of Life measured using QLQ-C30

    The changes from baseline to each visit where measured using QLQ-C30. EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Subject's responses to 28 questions about their physical functioning, disease symptoms, global health status and utilities are scored on a 4-point scale (1=Not at all to 4=Very much), a low score indicates a high / healthy level of functioning. And the responses to 2 questions about health-related QoL are scored on a 7-point scale (1=Very poor to 7=Excellent), a high score indicates a high / healthy level of functioning. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100.

    Time frame: Baseline, every 4 weeks until week 52, every 8 weeks after week 52 up to end of treatment or end of post-treatment follow-up, approximately 3.5 years.

  16. Pharmacokinetics (PK): Cmax

    Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants.

    Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.

  17. PK: Tmax

    Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants.

    Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.

  18. PK: AUC

    Full PK profile of eltrombopag over 24 hours at steady state at the initial dose, and at 125 mg and 150 mg when applicable, in subset of participants.

    Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.

  19. Trough concentrations of eltrombopag at steady state

    at each dose level in all the participants

    Time frame: Intensive: pre-dose, 1, 2, 4, 6, 8, and 24 hours post-dose. Trough: 15th days after starting the initial dose or each dose modification until reaching the maximum dose.

07

Study locations

20 sites
  • Novartis Investigative Site
    Narita, Chiba 2868523, Japan
  • Novartis Investigative Site
    Kurume, Fukuoka 8308543, Japan
  • Novartis Investigative Site
    Ohtake, Hiroshima 7390696, Japan
  • Novartis Investigative Site
    Nishinomiya, Hyōgo 6638501, Japan
  • Novartis Investigative Site
    Kanazawa, Ishikawa-ken 9208530, Japan
  • Novartis Investigative Site
    Isehara, Kanagawa 2591193, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 2210855, Japan
  • Novartis Investigative Site
    Sendai, Miyagi 9808574, Japan
  • Novartis Investigative Site
    Nagasaki, Nagasaki 8528501, Japan
  • Novartis Investigative Site
    Sakai, Osaka 5900197, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 1138603, Japan
  • Novartis Investigative Site
    Itabashi Ku, Tokyo 1738606, Japan
  • Novartis Investigative Site
    Shimonoseki, Yamaguchi 7500061, Japan
  • Novartis Investigative Site
    Aomori, 0308553, Japan
  • Novartis Investigative Site
    Chiba, 2600852, Japan
  • Novartis Investigative Site
    Fukushima, 9601295, Japan
  • Novartis Investigative Site
    Gifu, 5008513, Japan
  • Novartis Investigative Site
    Kumamoto, 8600008, Japan
  • Novartis Investigative Site
    Osaka, 5340021, Japan
  • Novartis Investigative Site
    Yamagata, 9909585, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Apr 2025, 47 months.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 47 months is above that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2021
First posted
Mar 15, 2021
StartActual
May 25, 2021
Primary completionActual
Apr 26, 2025
CompletionEst.
Dec 2, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 9, 2026→Dec 2, 2026
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Study completion Dec 9, 2026→Dec 2, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04797000
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
May 25, 2021
Primary completion
Apr 26, 2025
Completion
Dec 2, 2026 (estimated)
Last update
Oct 20, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion